U.N.: Pharma CMOs fare well in investment by developing nations

The United Nations Council for Trade and Development's 2011 World Investment Report, which identifies the top 10 pharma CMOs by manufacturing revenues, reveals a couple of other nuggets when one reads into it a little deeper.

Although Catalent Pharma Solutions takes top honors in terms of manufacturing revenue, it's the only U.S. CMO on the list. Lonza and Boehringer Ingelheim place second and third based on the 2009 figures.

Sliced by region and revenue, the top CMOs are:

  • Europe: Lonza, Boehringer Ingelheim, Royal DSM, Fareva Holding, Haupt: $4.178 billion combined;

  • North America: Catalent and Patheon: $2.17 billion combined;

  • India: Piramal and Jubilant: $1.435 billion combined; and 

  • Asia: NIPRO: $625 million.

That's 5 from Europe, two from North America, two from India and one from Japan.  It's not likely to stay that way when the U.N. gets around to tallying 2011 figures.

The report also finds that emerging economies are the new powerhouses of foreign direct investment (FDI), which is on the comeback trail--but still 15% below its pre-crisis average.

"Developing economies increased further in importance in 2010, both as recipients of FDI and as outward investors." Among them are China and South Africa.

Although manufacturing investments fell in some industries--notably metal and electronics--the chemical industry (including pharmaceuticals) "remained resilient" through the economic crisis, the report says. The food, beverages and tobacco, textiles and garments, and automobile industries actually began their recoveries in 2010.

The report also examines trends among transnational corporations. GlaxoSmithKline and Bayer are the two representatives of the pharma industry in the top 15 list of those having the largest percentage of their operating profits derived from operations in developing and transition economies.

- see the release
- here's an overview document (PDF)
- and here's the full report (PDF)

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.